# OnCo record maia (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/maia/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "maia", "NCT02252172" ;
  schema:name "MAIA"@en ;
  schema:description "MAIA showed that adding the antibody daratumumab to the standard two-drug regimen kept newly diagnosed myeloma under control for far longer in older people who cannot have a transplant, and later that they lived longer too, which made the three-drug regimen a standard first treatment."@en ;
  schema:url <https://onco.cc/trials/maia/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02252172> ;
  onco:status "positive" ;
  onco:tag "subtype-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/myeloma-transplant-ineligible/>, <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:drugs <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/dexamethasone/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> ;
  onco:people <https://onco.cc/people/thierry-facon/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-maia-daratumumab-rd-nejm-2019/> .